[1]
N. Dukic, Z. Gojkovic, J. Vladicic-Masic, S. Masic, N. Lalovic, and S. Popovic, “Adjuvant application of trastuzumab in HER2 positive breast cancer and impact on time to relapse”, Arch Oncol, vol. 26, no. 1, pp. 10–15, Jul. 2019, doi: 10.2298/AOO181112006D.